Effects of interleukin-18 on natural killer cells: Costimulation of activation through Fc receptors for immunoglobulin

Cancer Immunology, Immunotherapy

Volumn 62, Issue 6, 2013, Pages 1073-1082

  Srivastava, Shivani ^a,b   Pelloso, David ^a,b   Feng, Hailin ^a   Voiles, Larry ^c   Lewis, David ^c   Haskova, Zdenka ^d   Whitacre, Margaret ^d   Trulli, Stephen ^d   Chen, Yi Jiun ^d   Toso, John ^d   Jonak, Zdenka L ^d   Chang, Hua Chen ^c   Robertson, Michael J ^a,b  

^a Bone Marrow and Stem Cell Transplantation Program   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^c INDIANA UNIVERSITY   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Cancer immunotherapy; Cytokines; Lymphoma; Monoclonal antibodies; Rituximab

Indexed keywords

CD16 ANTIGEN; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD16; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE SYK INHIBITOR; RECOMBINANT INTERLEUKIN 18; RITUXIMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMOBILIZATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOMA; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAJI CELL; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; INTERFERON-GAMMA; INTERLEUKIN-18; KILLER CELLS, NATURAL; LYMPHOMA; MICE; NEOPLASMS; RECEPTORS, FC; RECEPTORS, IGG; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878830705     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1403-0     Document Type: Article

References (39)

1. Caligiuri MA (2008) Human natural killer cells. Blood 112(3):461-469
2. Robertson MJ, Ritz J (1990) Biology and clinical relevance of human natural killer cells. Blood 76:2421-2438
3. Leibson P (1997) Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity 6:655-661
4. Trotta R, Fettucciari K, Azzoni L, Abebe B, Puorro KA, Eisenlohr LC, Perussia B (2000) Differential role of p38 and c-Jun N-terminal kinase 1 mitogen-activated protein kinases in NK cell cytotoxicity. J Immunol 165:1782-1789
5. Roda JM, Parihar R, Magro C, Nuovo GJ, Tridandapani S, Carson WE (2006) Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated target cells. Cancer Res 66(1):517-526
6. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99:754-758
7. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A (2008) Immunoglobulin G fragment c receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26(11):1789-1796
8. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frebourg T, Michel P, Sabourin J-C, Boissiere-Michot F (2009) Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27(7):1122-1129
9. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 regulates both Th1 and Th2 responses. Ann Rev Immunol 19:423-474
10. Osaki T, Peron J-M, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT, Tahara H (1998) IFN-γ-inducing factor/IL-18 administration mediates IFN-γ- and IL-12-independent antitumor effects. J Immunol 160:1742-1749
11. Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Peron J-M, Lotze MT, Tahara H (1999) Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 163:583-589
12. Robertson MJ, Mier JW, Logan T, Atkins M, Koon H, Koch KM, Kathman S, Pandite LN, Oei C, Kirby LC, Jewell RC, Bell WN, Thurmond LM, Weisenbach J, Roberts S, Dar MM (2006) Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res 12(14):4265-4273
13. Robertson MJ, Kirkwood JM, Logan TF, Koch KM, Kathman S, Kirby LC, Bell WN, Thurmond LM, Weisenbach J, Dar MM (2008) A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res 14(11):3462-3469
14. Robertson MJ, Abonour R, Hromas R, Nelson RP, Fineberg NS, Cornetta K (2005) Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 46:1477-1487
15. Robertson MJ, Caligiuri MA, Manley TJ, Levine H, Ritz J (1990) Human natural killer cell adhesion molecules: differential expression after activation and participation in cytolysis. J Immunol 145:3194-3201
16. Chang H-C, Han L, Goswami R, Nguyen ET, Pelloso D, Robertson MJ, Kaplan MH (2009) Impaired development of human Th1 cells in patients with deficient expression of STAT4. Blood 113(23):5887-5890
17. Parihar R, Dierksheide J, Hu Y, Carson WE (2002) IL-12 enhances the natural killer cell cytokine response to Ab-coated target cells. J Clin Invest 110(7):983-992
18. Roda JM, Parihar R, Lehman A, Mani A, Tridandapani S, Carson WE (2006) Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 177:120-129
19. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA (1999) Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 162:4511-4520
20. Robertson MJ, Chang H-C, Pelloso D, Kaplan MH (2005) Impaired interferon-γ production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma. Blood 106:963-970
21. Robertson MJ, Pelloso D, Abonour R, Hromas RA, Nelson RP Jr, Wood L, Cornetta K (2002) Interleukin-12 immunotherapy after autologous stem cell transplantation for hematologic malignancies. Clin Cancer Res 8:3383-3393
22. Trotta R, Dal Col J, Yu J, Ciarlariello D, Thomas B, Zhang X, Allard J, Wei M, Mao H, Byrd JC, Perrotti D, Caligiuri MA (2008) TGF-β utilizes SMAD3 to inhibit CD16-mediated IFN-γ production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol 181:3784-3792
23. Perussia B, Trinchieri G, Jackson A, Warner NL, Faust J, Rumpold H, Kraft D, Lanier LL (1984) The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with monoclonal antibodies. J Immunol 133(1):180-189
24. Metes D, Ernst LK, Chambers WH, Sulica A, Herberman RB, Morel PA (1998) Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcγRIIC gene. Blood 91(7):2369-2380
25. Metes D, Manciulea M, Petrusca D, Rabinowich H, Ernst LK, Popescu I, Calugaru A, Sulica A, Chambers WH, Herberman RB, Morel PA (1999) Ligand binding specificities and signal transduction pathways of Fcγ receptor IIc isoforms: the CD32 isoforms expressed by human NK cells. Eur J Immunol 29:2842-2852
26. Cassatella MA, Anegon I, Cuturi MC, Griskey P, Trinchieri G, Perussia B (1989) Fcg R (CD16) interaction with ligand induces Ca2 + mobilization and phosphoinositide turnover in human natural killer cells: role of Ca2 + in Fcγ R (CD16)-induced transcription and expression of lymphokine genes. J Exp Med 169:549-567
27. Mailliard RB, Alber SM, Shen H, Watkins SC, Kirkwood JM, Herberman RB, Kalinski P (2005) IL-18-induced CD83 + CCR7 + NK helper cells. J Exp Med 202(7):941-953
28. Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol 75:163-189
29. Kondadasula SV, Roda JM, Parihar R, Yu J, Lehman A, Caligiuri MA, Tridandapani S, Burry RW, Carson WE (2008) Colocalization of the IL-12 receptor and FcγRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-g. Blood 111(8):4173-4183
30. Mavropoulos A, Sully G, Cope AP, Clark A (2004) Stabilization of IFN-γ mRNA by MAPK p38 in IL-12- and IL-18-stimulated human NK cells. Blood 105:282-288
31. Nakahira M, Ahn H-J, Park W-R, Gao P, Tomura M, Park C-S, Hamaoka T, Ohta T, Kurimoto M, Fujiwara H (2002) Synergy of IL-12 and IL-18 for IFN-γ gene expression: IL-12-induced STAT4 contributes to IFN-γ promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol 168:1146-1153
32. Zhang S, Kaplan MH (2000) The p38 mitogen-activated protein kinase is required for IL-12-induced IFN-γ expression. J Immunol 165:1375-1380
33. Robertson MJ (2002) Role of chemokines in the biology of natural killer cells. J Leukoc Biol 71:173-183
34. Overdijk MB, Verploegen S, Buijsse AO, Vink T, Leusen JHW, Bleeker WK, Parren PWHI (2012) Crosstalk between human IgG isotypes and murine effector cells. J Immunol 189:3430-3438
35. Daniel D, Yang B, Lawrence DA, Totpal K, Balter I, Lee WP, Gogineni A, Cole MJ, Yee SF, Ross S, Ashkenazi A (2007) Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 110:4037-4046
36. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS (2005) Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 11(16):5984-5992
37. Wigginton JM, Lee J-K, Wiltrout TA, Alvord WG, Hixon JA, Subleski J, Back TC, Wiltrout RH (2002) Syngergistic enhancement of ineffective endogenous antitumor immune response and induction of IFN-γ and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J Immunol 169:4467-4474
38. Jonak ZL, Trulli S, Maier C, McCabe FL, Kirkpatrick R, Johanson K, Ho YS, Elefante L, Chen Y-J, Herzyk D, Lotze MT, Johnson RK (2002) High-dose recombinant interleukin-18 induces an effective Th1 immune response to murine MOPC-315 plasmacytoma. J Immunother 25(Suppl. 1):S20-S27
39. Robertson MJ, Bauman J, Gardner O, Jonak Z, Struemper H, Germaschewski F, Koch KM, Murray S, Weisenbach J, Toso J (2011) A phase I trial evaluating the safety and biological activity of iboctadekin (rhIL-18) in combination with rituximab in patients with CD20 + B cell non-Hodgkin's lymphoma. Blood 118:1579-1580 (Abstract 3697)